Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
A phase 2 trial of Evorpacept, Pembrolizumab, Cisplatin in head and neck squamous cell carcinoma, run by ALX Oncology Inc., active and no longer recruiting.
Overview
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) is a phase 2 interventional study registered as NCT04675333 by ALX Oncology Inc., with 172 participants enrolled, started 2021-05-10 and due to reach its primary completion in 2025-03-03. Interventions recorded: evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU. Conditions listed: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialEvorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Shares ALX Oncology, Evorpacept, Head and neck squamous cell carcinoma, Pembrolizumab.
- TrialA Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Shares ALX Oncology, Evorpacept.
- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Cisplatin, Carboplatin, Head and neck squamous cell carcinoma, Pembrolizumab.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares ALX Oncology, Evorpacept.
- TrialEfficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Shares Cisplatin, Carboplatin, Head and neck squamous cell carcinoma, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Shares Cisplatin, Carboplatin, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Shares Cisplatin, Carboplatin, Pembrolizumab.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Shares Fluorouracil (5-FU), Cisplatin, Pembrolizumab.